Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) shares were up 8.4% during trading on Wednesday . The company traded as high as $19.89 and last traded at $19.79. Approximately 220,548 shares changed hands during mid-day trading, a decline of 17% from the average daily volume of 264,374 shares. The stock had previously closed at $18.25.
Analysts Set New Price Targets
A number of analysts have recently commented on DNTH shares. Guggenheim reissued a "buy" rating and issued a $84.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. William Blair started coverage on Dianthus Therapeutics in a research note on Wednesday, July 2nd. They issued an "outperform" rating on the stock. Robert W. Baird dropped their price objective on Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 13th. Wedbush reaffirmed an "outperform" rating and set a $36.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research report on Tuesday, May 13th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $53.00.
View Our Latest Report on DNTH
Dianthus Therapeutics Stock Down 3.2%
The business has a 50-day moving average price of $18.70 and a 200-day moving average price of $20.37. The company has a market capitalization of $656.71 million, a price-to-earnings ratio of -7.11 and a beta of 1.38.
Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.82) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.86) by $0.04. Dianthus Therapeutics had a negative return on equity of 29.26% and a negative net margin of 1,544.23%. The company had revenue of $1.16 million for the quarter, compared to analyst estimates of $0.81 million. As a group, sell-side analysts predict that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of the business. MetLife Investment Management LLC grew its holdings in shares of Dianthus Therapeutics by 3.1% during the fourth quarter. MetLife Investment Management LLC now owns 14,372 shares of the company's stock valued at $313,000 after buying an additional 433 shares in the last quarter. ADAR1 Capital Management LLC grew its holdings in shares of Dianthus Therapeutics by 3.4% during the first quarter. ADAR1 Capital Management LLC now owns 18,285 shares of the company's stock valued at $332,000 after buying an additional 602 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Dianthus Therapeutics by 4.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company's stock valued at $280,000 after buying an additional 618 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Dianthus Therapeutics by 1.0% during the first quarter. Bank of New York Mellon Corp now owns 73,638 shares of the company's stock valued at $1,336,000 after buying an additional 748 shares in the last quarter. Finally, Invesco Ltd. grew its holdings in shares of Dianthus Therapeutics by 7.4% during the fourth quarter. Invesco Ltd. now owns 11,521 shares of the company's stock valued at $251,000 after buying an additional 790 shares in the last quarter. Hedge funds and other institutional investors own 47.53% of the company's stock.
About Dianthus Therapeutics
(
Get Free Report)
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Further Reading
Before you consider Dianthus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dianthus Therapeutics wasn't on the list.
While Dianthus Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
